Clinical trial • Phase II • Neurology
Clinical trial in Migraine
Phase II trial for Migraine. 36 participants.
Overview
- Trial Therapeutic Area
- Neurology
- Trial Disease
- Migraine
- Trial Stage
- Phase II
Key dates
- Initial CTIS Submission Date
- 16-03-2026
- First CTIS Authorization Date
- 28-04-2026
Trial design
Phase II trial across 1 site in Belgium.
- Target Sample Size
- 36
Eligibility
Recruits 36 Vulnerable population selected: Yes. Population: Healthy volunteers. No consent or assent details provided in the record..
- Vulnerable Population
- Vulnerable population selected: Yes. Population: Healthy volunteers. No consent or assent details provided in the record.
Recruitment
- Planned Sample Size
- 36
- Recruitment Window Months
- 3
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 36
Belgium
- Earliest CTIS Part Ii Submission Date
- 17-04-2026
- Latest Decision Or Authorization Date
- 28-04-2026
- Processing Time Days
- 11
- Number Of Sites
- 1
- Number Of Participants
- 36
Sites
- Site Name
- Pfizer Clinical Research Unit
- Contact Person Name
- Laure Mendes da Costa
- Contact Person Email
- PfizerVolRecruitment@pfizer.com
Sponsor
Primary sponsor
- Full Name
- Pfizer Inc.
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- United States
Related trials
Other published trials that may interest you.